Objective To investigate the clinical significance of βisomer of C-terminal telopeptide (β-CTX) in Zoledronic acid (ZOL) combined with chemotherapy for non-small cell lung cancer (NSCLC) with bone metastasis. MethodsNewly diagnosed NSCLC patients with bone metastasis (n=60) were randomised to the test group (n=30), who received ZOL combined with chemotherapy, or a control group (n=30), who received chemotherapy alone. Serum β-CTX was measured by ELISA before and after treatment in two groups. ResultsThe total effective rate was 90.00% in the treatment group were higher than that of the control group (63.33%) (P<0.05). The level of β-CTX after treatment in treatment group was lower than that before treatment (P<0.05), while in control group had no significant difference (P>0.05). ConclusionZOL administered with chemotherapy can more effectively reduce β-CTX levels for NSCLC patients with bone metastasis. Indicating that the change of β-CTX might be as a valuable index to ZOL for the treatment of NSCLC patients with bone metastasis.